DUBLIN–(BUSINESS WIRE)–The “Carrier Screening Market Share, Size, Trends, Industry Analysis Report, By Type; By Medical Condition; By Technology; By End-User; By Regions; Segment Forecast, 2022 – 2030” report has been added to ResearchAndMarkets.com’s offering.
The global carrier screening market size is expected to reach USD 3.64 billion by 2030, according to a new study. The report gives a detailed insight into current market dynamics and provides analysis on future market growth.
The well-established healthcare infrastructure and the rise in innovative product introductions are driving the expansion of the industry. Many countries concentrate their efforts on developing enhanced medical infrastructure that includes enhanced treatment techniques.
Furthermore, developed-country nations have modern healthcare infrastructure integrated with various transmission methods, pushing the rise and need for these techniques throughout such countries. Many people wish to discover if their genetic or inherited disorders might be transmitted to their offerings.
As a result, these factors are expected to open up promising growth opportunities for companies in the overall industry during the forecasted period.
Additionally, the increasing prevalence of fetal chromosomal abnormalities boosts industry growth. According to the WHO, congenital abnormalities are major causes of fetal and infant mortality, chronic illness, and disabilities. Every year, an estimated 295 000 newborns nationwide die within 28 days of birth due to congenital abnormalities.
Thus, the rising prevalence of fetal abnormalities, increasing product launches, and established healthcare infrastructure propel the industry growth during the forecast period.
Market Dynamics
Drivers and Opportunities
- Increasing emphasis on early disease detection & prevention
- Increasing awareness of carrier screening
Restraints and Challenges
- High cost of service
Companies Mentioned
- 23Andme Inc.
- Abbott Laboratories
- Autogenomics Inc.
- Danaher Corporation
- Eurofins Scientific
- Fulgent Genetics Inc.
- Illumina Inc.
- Invitae Corporation
- Luminex Corporation
- MedGenome
- Myriad Genetics
- Natera Inc.
- Opko Health
- Quest Diagnostics Incorporated
- Roche AG
- Sequenom Inc.
- Thermo Fisher Scientific Inc.
- True Health
The publisher has segmented the carrier screening market report based on type, medical condition, technology, end-user, and region:
Carrier Screening, Type Outlook
- Expanded
- Customized Panel Testing
- Predesigned Panel Testing
- Targeted Disease
Carrier Screening, Medical Condition Outlook
- Pulmonary Conditions
- Hematological Conditions
- Neurological Conditions
- Other Conditions
Carrier Screening, Technology Outlook
- DNA Sequencing
- Polymerase Chain Reaction
- Microarrays
- Other Technologies
Carrier Screening, End-User Outlook
- Hospitals
- Reference Laboratories
- Physician Offices & Clinics
- Other End Users
Carrier Screening, Regional Outlook
- North America
- U.S.
- Canada
- Europe
- France
- Germany
- UK
- Italy
- Netherlands
- Spain
- Austria
- Asia Pacific
- China
- India
- Japan
- Malaysia
- South Korea
- Indonesia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
For more information about this report visit https://www.researchandmarkets.com/r/tiotot
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
